Arcutis stock falls after Q3 earnings miss (ARQT:NASDAQ)
Arcutis Biotherapeutics (ARQT) reported Q3 2026 earnings that missed estimates due to higher expenses, causing its stock to drop 20%. Revenue rose 45% YoY to $143.9M, exceeding consensus by $1.3M, according to the company.
How this was made
The 30-second read
Why it matters
The earnings miss triggered a near 20% stock decline, indicating immediate downside risk.
Market read
The surprise earnings shortfall provides a clear short-term trading signal for ARQT.
What to watch
Potential pipeline milestones not covered in the brief could offset short-term weakness.
Background
Arcutis Biotherapeutics is a dermatology-focused biotech listed on NASDAQ.
Ticker impact
Arcutis reported Q3 earnings miss, shares fell ~20% after results showed higher expenses and revenue $143.9M.
downward pressure as market prices in the earnings shortfall
Revenue beat was modest while expenses surprised to the upside, leading to a sharp share decline.
Market effects
Dermatology biotech sector may see broader risk reassessment.
US biotech indices could dip slightly.
Limited to investors in biotech and small-cap US equities.
Counterpoint
Revenue beat could suggest upside if expense growth is temporary.
Key entities
- CompanyArcutis Biotherapeutics
NASDAQ-listed biotech reporting Q3 2026 results.

